VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of VYNE Therapeutics (NASDAQ:VYNE) from a sell rating to a hold rating in a research report report published on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, VYNE Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $4.50.

VYNE Therapeutics Stock Down 0.0%

VYNE opened at $0.57 on Friday. The company has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.51. The stock has a market capitalization of $18.87 million, a price-to-earnings ratio of -0.73 and a beta of 1.95. VYNE Therapeutics has a twelve month low of $0.28 and a twelve month high of $3.08.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.13 million. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%. Sell-side analysts anticipate that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYNE. Patient Square Capital LP boosted its position in shares of VYNE Therapeutics by 23.3% during the second quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock valued at $523,000 after purchasing an additional 60,000 shares in the last quarter. Kennedy Capital Management LLC bought a new stake in VYNE Therapeutics in the 2nd quarter worth approximately $942,000. Velan Capital Investment Management LP purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth $50,000. TFG Asset Management GP Ltd purchased a new position in VYNE Therapeutics during the second quarter valued at approximately $190,000. Finally, Jane Street Group LLC purchased a new position in VYNE Therapeutics in the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.